NCT04134468View on ClinicalTrials.gov

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

January 31, 2020

Primary Completion Date

February 11, 2021

Study Completion Date

November 11, 2022

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

Pegvorhyaluronidase alfa

IV infusion

DRUG

Abraxane

IV infusion

DRUG

Gemcitabine

IV infusion

Trial Locations (1)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Halozyme Therapeutics

All Listed Sponsors

collaborator

Halozyme Therapeutics

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER